BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma

First program from BioNTech's fully-owned mRNA cancer vaccine platform FixVac treats patients in a randomized clinical Phase 2 clinical trial